

Bench to bedside: elucidation of the OPGâ€“RANKâ€“R denosumab

Nature Reviews Drug Discovery

11, 401-419

DOI: [10.1038/nrd3705](https://doi.org/10.1038/nrd3705)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New developments in osteoimmunology. Nature Reviews Rheumatology, 2012, 8, 684-689.	3.5	213
2	SnapShot: Bone Metastasis. Cell, 2012, 151, 690-690.e1.	13.5	97
3	Osteoclast Biology. , 2013, , 149-160.		5
4	NSAIDs can have adverse effects on bone healing. Medical Hypotheses, 2013, 81, 343-346.	0.8	41
5	Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 1261-1283.	0.9	5
6	Genome-wide expression profiles of subchondral bone in osteoarthritis. Arthritis Research and Therapy, 2013, 15, R190.	1.6	103
7	Protein phosphatase 2A C \hat{I} ± is involved in osteoclastogenesis by regulating RANKL and OPG expression in osteoblasts. FEBS Letters, 2013, 587, 48-53.	1.3	22
8	Clinical targeting of the TNF and TNFR superfamilies. Nature Reviews Drug Discovery, 2013, 12, 147-168.	21.5	364
9	Biomedical applications of bisphosphonates. Journal of Controlled Release, 2013, 167, 175-188.	4.8	147
10	Importance of reverse signaling of the TNF superfamily in immune regulation. Expert Review of Clinical Immunology, 2013, 9, 335-348.	1.3	56
11	Cellular Players in Breast Cancer Bone Metastases. Clinical Reviews in Bone and Mineral Metabolism, 2013, 11, 122-132.	1.3	1
12	Immunology and bone. Journal of Biochemistry, 2013, 154, 29-39.	0.9	93
13	Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis. Future Oncology, 2013, 9, 1609-1622.	1.1	19
14	Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies. Aging Clinical and Experimental Research, 2013, 25, 19-22.	1.4	3
16	Establishment of OPG Transgenic Mice and the Effect of OPG on Bone Microarchitecture. International Journal of Endocrinology, 2013, 2013, 1-7.	0.6	7
17	The Role of Vascular Endothelial Growth Factor in Metastatic Prostate Cancer to the Skeleton. Prostate Cancer, 2013, 2013, 1-8.	0.4	94
18	Denosumab for the Treatment of Osteoporosis. , 2013, , 1923-1934.		0
19	Static and Dynamic Hypergravity Responses of Osteoblasts and Osteoclasts in Medaka Scales. Zoological Science, 2013, 30, 217-223.	0.3	11

#	ARTICLE	IF	CITATIONS
20	The Protective Effects of Î²-Cryptoxanthin on Inflammatory Bone Resorption in a Mouse Experimental Model of Periodontitis. <i>Bioscience, Biotechnology and Biochemistry</i> , 2013, 77, 860-862.	0.6	19
21	A "vicious cycle" of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?. <i>Oncology</i> , 2013, 2, e23850.	2.1	14
22	IL-17 Mediated M1/M2 Macrophage Alteration Contributes to Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaws. <i>Clinical Cancer Research</i> , 2013, 19, 3176-3188.	3.2	126
23	RANKL Cytokine: From Pioneer of the Osteoimmunology Era to Cure for a Rare Disease. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-9.	3.3	30
25	Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan. <i>Japanese Journal of Clinical Immunology</i> , 2013, 36, 209-216.	0.0	3
26	Exploring Codon Optimization and Response Surface Methodology to Express Biologically Active Transmembrane RANKL in <i>E. coli</i> . <i>PLoS ONE</i> , 2014, 9, e96259.	1.1	17
27	RANK rs1805034 T>C Polymorphism Is Associated with Susceptibility of Esophageal Cancer in a Chinese Population. <i>PLoS ONE</i> , 2014, 9, e101705.	1.1	13
28	Receptor activator of nuclear factor kappa-B gene polymorphisms in Iranian periodontitis and peri-implantitis patients. <i>Journal of Periodontal and Implant Science</i> , 2014, 44, 141.	0.9	4
29	Neurostimulation of the Cholinergic Antiinflammatory Pathway in Rheumatoid Arthritis and Inflammatory Bowel Disease. <i>Bioelectronic Medicine</i> , 2014, 1, 34-43.	1.0	12
30	Modulation of osteoclast differentiation and bone resorption by Rho GTPases. <i>Small GTPases</i> , 2014, 5, e28119.	0.7	73
31	The Inhibition of RANKL-Induced Osteoclastogenesis through the Suppression of p38 Signaling Pathway by Naringenin and Attenuation of Titanium-Particle-Induced Osteolysis. <i>International Journal of Molecular Sciences</i> , 2014, 15, 21913-21934.	1.8	27
32	Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. <i>Frontiers in Immunology</i> , 2014, 5, 511.	2.2	469
33	Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: A novel ONJ mouse model. <i>Bone</i> , 2014, 68, 11-19.	1.4	57
35	Similar Relationship Between the Time Course of Bone Mineral Density Improvement and Vertebral Fracture Risk Reduction With Denosumab Treatment in Postmenopausal Osteoporosis and Prostate Cancer Patients on Androgen Deprivation Therapy. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 503-512.	1.0	6
36	The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression. <i>Journal of Bone Oncology</i> , 2014, 3, 67-76.	1.0	11
37	Role of bone-anabolic agents in the treatment of breast cancer bone metastases. <i>Breast Cancer Research</i> , 2014, 16, 484.	2.2	35
38	Osteoclast Derivation from Mouse Bone Marrow. <i>Journal of Visualized Experiments</i> , 2014, , e52056.	0.2	24
39	Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H ⁺ -ATPase as an emerging target. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 505-522.	2.5	34

#	ARTICLE	IF	CITATIONS
40	The multidisciplinary management of giant cell tumor of bone. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 783-790.	1.1	13
41	Epigenetic mechanisms in bone. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 589-608.	1.4	75
42	Advancing therapeutic discovery through phenotypic screening of the extracellular proteome using hydrodynamic intravascular injection. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1253-1264.	1.5	3
43	Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members. <i>Science Signaling</i> , 2014, 7, ra80.	1.6	11
44	Targeting RANKL in metastasis. <i>BoneKEy Reports</i> , 2014, 3, 519.	2.7	60
45	Polychlorinated biphenyl (118) activates osteoclasts and induces bone resorption in goldfish. <i>Environmental Science and Pollution Research</i> , 2014, 21, 6365-6372.	2.7	14
46	A brilliant breakthrough in OI type V. <i>Osteoporosis International</i> , 2014, 25, 399-405.	1.3	6
47	Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 502-509.	0.9	68
48	Antiresorptive Drug-Related Osteonecrosis of the Jaw. <i>Dental Clinics of North America</i> , 2014, 58, 369-384.	0.8	36
49	Effects of Denosumab Treatment and Discontinuation on Human Growth Plates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 891-897.	1.8	57
50	American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014, 72, 1938-1956.	0.5	2,019
51	Omic-profiling in breast cancer metastasis to bone: Implications for mechanisms, biomarkers and treatment. <i>Cancer Treatment Reviews</i> , 2014, 40, 139-152.	3.4	31
52	RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 843-854.	3.1	81
53	Absorption, distribution and mechanism of action of SYSADOAS. , 2014, 142, 362-374.		82
54	The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. <i>Bone</i> , 2014, 60, 8-15.	1.4	50
55	RANK expression on breast cancer cells promotes skeletal metastasis. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 233-245.	1.7	48
56	Current Treatment Modalities for Spinal Metastases Secondary to Thyroid Carcinoma. <i>Thyroid</i> , 2014, 24, 1443-1455.	2.4	37
57	Osteoporosis. <i>Seminars in Nuclear Medicine</i> , 2014, 44, 439-450.	2.5	46

#	ARTICLE	IF	CITATIONS
58	Osteoclasts: more than "bone eaters"™. Trends in Molecular Medicine, 2014, 20, 449-459.	3.5	301
59	Osteoprotegerin and kidney disease. Journal of Nephrology, 2014, 27, 607-617.	0.9	34
60	Getting TRAIL back on track for cancer therapy. Cell Death and Differentiation, 2014, 21, 1350-1364.	5.0	392
61	Stage 0 Osteonecrosis of the Jaw in a Patient on Denosumab. Journal of Oral and Maxillofacial Surgery, 2014, 72, 702-716.	0.5	35
62	The effect of dose on rhBMP-2 signaling, delivered via collagen sponge, on osteoclast activation and in vivo bone resorption. Biomaterials, 2014, 35, 1869-1881.	5.7	52
63	Involvement of CXCL14 in osteolytic bone metastasis from lung cancer. International Journal of Oncology, 2014, 44, 1316-1324.	1.4	21
64	Why Platelet-Rich Plasma Failed to Promote Bone Healing in Combination With a Biphasic Synthetic Graft Material in Bone Defects. Journal of Craniofacial Surgery, 2014, 25, 1568-1569.	0.3	0
65	Receptor activator of nuclear factor- κ B ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (Review). Molecular Medicine Reports, 2015, 11, 3212-3218.	1.1	168
67	Runx2 α signaling impacts the progression of tumor-induced bone disease. International Journal of Cancer, 2015, 136, 1321-1332.	2.3	26
68	Ablation of Tak1 in osteoclast progenitor leads to defects in skeletal growth and bone remodeling in mice. Scientific Reports, 2014, 4, 7158.	1.6	20
69	Adiponectin exacerbates collagen-induced arthritis via enhancing Th17 response and prompting RANKL expression. Scientific Reports, 2015, 5, 11296.	1.6	38
70	Serum RANKL levels associate with anti-citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate. Arthritis Research and Therapy, 2015, 17, 239.	1.6	45
71	OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice. Journal of Bone and Mineral Research, 2015, 30, 1627-1640.	3.1	57
73	<i>In vivo</i> osteoprotegerin gene therapy preventing bone loss induced by periodontitis. Journal of Periodontal Research, 2015, 50, 434-443.	1.4	16
75	Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw – work in progress and challenges. Clinical Epidemiology, 2015, 7, 107.	1.5	15
76	Giant-cell tumor of bone: treatment options and role of denosumab. Biologics: Targets and Therapy, 2015, 9, 69.	3.0	49
77	Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. PLoS ONE, 2015, 10, e0128467.	1.1	9
78	RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients. PLoS ONE, 2015, 10, e0133964.	1.1	25

#	ARTICLE	IF	CITATIONS
79	The Role of "Bone Immunological Niche" for a New Pathogenetic Paradigm of Osteoporosis. Analytical Cellular Pathology, 2015, 2015, 1-10.	0.7	14
80	Acidic microenvironment and bone pain in cancer-colonized bone. BoneKEy Reports, 2015, 4, 690.	2.7	48
81	Plasminogen Activator System " Diagnostic, Prognostic and Therapeutic Implications in Breast Cancer. , 2015, , .		3
82	A Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis Mediated Through FoxP3+ CD8 T Cells. Journal of Bone and Mineral Research, 2015, 30, 1508-1522.	3.1	27
83	Cancer bronchique et inflammation. Revue Des Maladies Respiratoires Actualites, 2015, 7, 554-563.	0.0	1
84	The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. Arthritis Research and Therapy, 2015, 17, 251.	1.6	36
85	Role of osteoprotegerin in vascular disorders of the end-stage renal disease patients. Biomarkers, 2015, 20, 116-122.	0.9	4
86	Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model. Acta Biomaterialia, 2015, 13, 150-158.	4.1	36
87	Osteoprotegerin Protects against Muscular Dystrophy. American Journal of Pathology, 2015, 185, 920-926.	1.9	47
88	Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2677-2684.	1.4	59
89	The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer. Molecular and Cellular Biochemistry, 2015, 403, 219-229.	1.4	19
90	Receptor activating NF- κ B ligand (RANKL) is a constitutive intracellular protein in resting human basophils and is strongly induced on their surface by interleukin 3. Immunobiology, 2015, 220, 692-700.	0.8	10
91	Drugs Used in Paediatric Bone and Calcium Disorders. Endocrine Development, 2015, 28, 277-290.	1.3	7
92	Association of estrogen receptor β and estrogen-related receptor α gene polymorphisms with bone mineral density in postmenopausal women. Molecular and Cellular Biochemistry, 2015, 405, 23-31.	1.4	12
93	Down the line from genome-wide association studies in inflammatory bowel disease: the resulting clinical benefits and the outlook for the future. Expert Review of Clinical Immunology, 2015, 11, 33-44.	1.3	13
95	Improved efficacy of soluble human receptor activator of nuclear factor kappa B (RANK) fusion protein by site-directed mutagenesis. Immunopharmacology and Immunotoxicology, 2015, 37, 221-227.	1.1	0
96	Histopathology of skeletal metastases. , 2015, , 461-470.		0
97	Piroxicam Treatment Augments Bone Abnormalities in Interleukin-10 Knockout Mice. Inflammatory Bowel Diseases, 2015, 21, 257-266.	0.9	13

#	ARTICLE	IF	CITATIONS
98	Erythropoietin directly stimulates osteoclast precursors and induces bone loss. <i>FASEB Journal</i> , 2015, 29, 1890-1900.	0.2	95
99	Identification of metals from osteoblastic ST-2 cell supernatants as novel OGR1 agonists. <i>Journal of Receptor and Signal Transduction Research</i> , 2015, 35, 485-492.	1.3	10
100	Pathophysiology of Osteonecrosis of the Jaws. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2015, 27, 489-496.	0.4	128
101	Palliative Oncology. <i>American Journal of Hospice and Palliative Medicine</i> , 2015, 32, 568-572.	0.8	15
102	RANK and RANK ligand expression in primary human osteosarcoma. <i>Journal of Bone Oncology</i> , 2015, 4, 59-68.	1.0	47
103	Osteoprotegerin in breast cancer: beyond bone remodeling. <i>Molecular Cancer</i> , 2015, 14, 117.	7.9	49
104	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv256.	3.0	90
105	RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?. <i>Oncology</i> , 2015, 88, 257-260.	0.9	37
106	Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ). <i>Clinical Oral Investigations</i> , 2015, 19, 1307-1318.	1.4	22
107	Heptamethoxyflavone, a citrus flavonoid, suppresses inflammatory osteoclastogenesis and alveolar bone resorption. <i>Bioscience, Biotechnology and Biochemistry</i> , 2015, 79, 155-158.	0.6	10
108	Bone resorption correlates with the frequency of CD5+ B cells in the blood of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 545-553.	0.9	7
109	A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw. <i>Journal of Hard Tissue Biology</i> , 2016, 25, 447-454.	0.2	5
110	RANK and RANKL of Bones, T Cells, and the Mammary Glands. , 2016, , 121-142.		1
111	Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw. <i>Journal of the Korean Association of Oral and Maxillofacial Surgeons</i> , 2016, 42, 271.	0.3	8
112	Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. <i>Immunological Reviews</i> , 2016, 271, 260-275.	2.8	277
113	Overexpression of RANKL in osteoblasts: a possible mechanism of susceptibility to bone disease in cystic fibrosis. <i>Journal of Pathology</i> , 2016, 240, 50-60.	2.1	20
115	RANKL/RANK: from bone loss to the prevention of breast cancer. <i>Open Biology</i> , 2016, 6, 160230.	1.5	53
116	Bone targeted treatments in cancer – The story so far. <i>Journal of Bone Oncology</i> , 2016, 5, 90-92.	1.0	12

#	ARTICLE	IF	CITATIONS
117	Dioscin reduces ovariectomy-induced bone loss by enhancing osteoblastogenesis and inhibiting osteoclastogenesis. <i>Pharmacological Research</i> , 2016, 108, 90-101.	3.1	45
118	Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. <i>Vascular Pharmacology</i> , 2016, 82, 30-40.	1.0	103
119	LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. <i>Nature Medicine</i> , 2016, 22, 539-546.	15.2	278
120	The intervening removable affinity tag (iRAT) production system facilitates Fv antibody fragment-mediated crystallography. <i>Protein Science</i> , 2016, 25, 2268-2276.	3.1	7
121	Rapid phenotyping of knockout mice to identify genetic determinants of bone strength. <i>Journal of Endocrinology</i> , 2016, 231, R31-R46.	1.2	30
122	Sodium fluoride induces hypercalcemia resulting from the upregulation of both osteoblastic and osteoclastic activities in goldfish, <i>Carassius auratus</i> . <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2016, 189, 54-60.	1.3	3
123	Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1827-1834.	3.1	60
124	The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6. <i>Open Biology</i> , 2016, 6, 160120.	1.5	12
125	Explaining RANKL inhibition by OPG through quantum biochemistry computations and insights into peptide-design for the treatment of osteoporosis. <i>RSC Advances</i> , 2016, 6, 84926-84942.	1.7	7
126	Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss. <i>Scientific Reports</i> , 2016, 6, 30998.	1.6	15
127	Antibodies for the Treatment of Bone Diseases: Clinical Data. , 2016, , 239-255.		0
128	Activation of mTORC1 in B Lymphocytes Promotes Osteoclast Formation via Regulation of β -Catenin and RANKL/OPG. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1320-1333.	3.1	36
129	Hypercalcemia after discontinuation of long-term denosumab treatment. <i>Osteoporosis International</i> , 2016, 27, 2383-2386.	1.3	34
130	Real-time intravital imaging of pH variation associated with osteoclast activity. <i>Nature Chemical Biology</i> , 2016, 12, 579-585.	3.9	80
131	Prevention of breast cancer by RANKL/RANK blockade. <i>Cell Research</i> , 2016, 26, 751-752.	5.7	5
132	p38 β MAPK Regulates Lineage Commitment and OPG Synthesis of Bone Marrow Stromal Cells to Prevent Bone Loss under Physiological and Pathological Conditions. <i>Stem Cell Reports</i> , 2016, 6, 566-578.	2.3	32
133	Discovery and bio-optimization of human antibody therapeutics using the XenoMouse [®] transgenic mouse platform. <i>Immunological Reviews</i> , 2016, 270, 51-64.	2.8	25
134	Identification of crucial genes related to postmenopausal osteoporosis using gene expression profiling. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1067-1074.	1.4	18

#	ARTICLE	IF	CITATIONS
135	<sc>RANK</sc> as a therapeutic target in cancer. FEBS Journal, 2016, 283, 2018-2033.	2.2	47
136	Role of the RANK/RANKL pathway in breast cancer. Maturitas, 2016, 86, 10-16.	1.0	48
137	Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside—a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2016, 51, 27-47.	2.9	50
138	Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect. Bone, 2016, 84, 93-103.	1.4	48
139	Effects of denosumab on peripheral lymphocyte subpopulations. Endocrine, 2016, 53, 857-859.	1.1	9
140	Murine <i>Rankl</i> ^{-/-} Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector. Stem Cells, 2017, 35, 1365-1377.	1.4	18
141	Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort. Acta Oncologica, 2017, 56, 479-483.	0.8	23
142	Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. British Dental Journal, 2017, 222, 121-125.	0.3	42
143	State of the art in anti-cancer mAbs. Journal of Biomedical Science, 2017, 24, 15.	2.6	64
144	Human Adipose-Derived Mesenchymal Stem Cells for Osseous Rehabilitation of Induced Osteoradionecrosis: A Rodent Model. Otolaryngology - Head and Neck Surgery, 2017, 156, 616-621.	1.1	14
145	Prognosis of local recurrence in giant cell tumour of bone: what can we do?. Radiologia Medica, 2017, 122, 505-519.	4.7	15
146	Physiopathologie des métastases osseuses des tumeurs solides. Revue Du Rhumatisme Monographies, 2017, 84, 107-114.	0.0	1
147	Can Lumbar Spine Bone Mineral Density Predict Readmission in Denosumab-Treated Patients with Chronic Kidney Disease?. Journal of Investigative Medicine, 2017, 65, 53-56.	0.7	4
148	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Research and Treatment, 2017, 164, 57-67.	1.1	31
149	Pathophysiology of bone metastases from solid malignancies. Joint Bone Spine, 2017, 84, 677-684.	0.8	38
150	Bone Size and Quality Regulation: Concerted Actions of mTOR in Mesenchymal Stromal Cells and Osteoclasts. Stem Cell Reports, 2017, 8, 1600-1616.	2.3	29
151	Sodium fluoride influences calcium metabolism resulting from the suppression of osteoclasts in the scales of nibbler fish <i>Girella punctata</i> . Fisheries Science, 2017, 83, 543-550.	0.7	11
152	Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 299-307.	0.6	9

#	ARTICLE	IF	CITATIONS
153	Bone-seeking agents for the treatment of bone disorders. <i>Drug Delivery and Translational Research</i> , 2017, 7, 466-481.	3.0	18
154	Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. <i>Journal of Leukocyte Biology</i> , 2017, 102, 393-406.	1.5	55
155	Pharmacologic Calcitriol Inhibits Osteoclast Lineage Commitment via the BMP-Smad1 and $\text{IL-1}\beta$ -NF- κ B Pathways. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1406-1420.	3.1	26
156	Sortase A-aided <i>Escherichia coli</i> expression system for functional osteoprotegerin cysteine-rich domain. <i>Applied Microbiology and Biotechnology</i> , 2017, 101, 4923-4933.	1.7	1
157	p38 β MAPK regulates proliferation and differentiation of osteoclast progenitors and bone remodeling in an aging-dependent manner. <i>Scientific Reports</i> , 2017, 7, 45964.	1.6	64
158	Metformin inhibits <i>RANKL</i> and sensitizes cancer stem cells to denosumab. <i>Cell Cycle</i> , 2017, 16, 1022-1028.	1.3	19
159	Estrogen stimulates osteoprotegerin expression via the suppression of miR-145 expression in MG-63 cells. <i>Molecular Medicine Reports</i> , 2017, 15, 1539-1546.	1.1	40
160	Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 198-202.	3.1	181
161	RANKL release from self-assembling nanofiber hydrogels for inducing osteoclastogenesis in vitro. <i>Acta Biomaterialia</i> , 2017, 49, 306-315.	4.1	18
162	Comparison of the effects of once-weekly and once-daily rhPTH (1-34) injections on promoting fracture healing in rodents. <i>Journal of Orthopaedic Research</i> , 2018, 36, 1145-1152.	1.2	9
163	The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing. <i>Scientific Reports</i> , 2017, 7, 13459.	1.6	43
164	Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF- κ B and Its Ligand. <i>ChemMedChem</i> , 2017, 12, 1697-1702.	1.6	2
165	Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 148, 203-303.	0.9	151
166	TGF β 2 induced PAR1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone. <i>International Journal of Cancer</i> , 2017, 141, 1630-1642.	2.3	17
167	Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 614-621.	1.0	23
168	A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma. <i>Journal of Bone Oncology</i> , 2017, 8, 4-7.	1.0	31
169	How Basic Science Discoveries Have Shaped the Treatment of Bone and Mineral Disorders. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2324-2330.	3.1	1
170	Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis. <i>Bone Reports</i> , 2017, 7, 164-171.	0.2	6

#	ARTICLE	IF	CITATIONS
171	Osteoporosis treatment: recent developments and ongoing challenges. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 898-907.	5.5	615
173	Updates on the role of receptor activator of nuclear factor $\hat{\text{P}}\text{B}$ /receptor activator of nuclear factor $\hat{\text{P}}\text{B}$ ligand/osteoprotegerin pathway in breast cancer risk and treatment. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 4-11.	0.9	10
174	Lutein, a carotenoid, suppresses osteoclastic bone resorption and stimulates bone formation in cultures. <i>Bioscience, Biotechnology and Biochemistry</i> , 2017, 81, 302-306.	0.6	16
175	Using GWAS to identify novel therapeutic targets for osteoporosis. <i>Translational Research</i> , 2017, 181, 15-26.	2.2	45
176	Medication-Related Osteonecrosis of the Jaw: a Brief Review, Treatment and Practical Guidelines for Dentists. <i>Journal of Interdisciplinary Medicine</i> , 2017, 2, 117-121.	0.1	0
177	Effects of <i>Salvia miltiorrhiza</i> extract with supplemental liquefied calcium on osteoporosis in calcium-deficient ovariectomized mice. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 545.	3.7	20
178	Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss. <i>Frontiers in Immunology</i> , 2017, 8, 1851.	2.2	32
179	Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 108.	3.5	97
180	Biomaterial-Mediated Drug Delivery in Primary and Metastatic Cancers of the Bone. , 2017, , 569-604.		1
181	Molecular mechanisms of the inhibitory effects of jiangsu granule-containing serum on RANKL-induced osteoclastogenesis. <i>Molecular Medicine Reports</i> , 2017, 16, 8420-8426.	1.1	4
182	Effects of low-intensity pulsed ultrasound on osteoclasts: Analysis with goldfish scales as a model of bone . <i>Biomedical Research</i> , 2017, 38, 71-77.	0.3	13
183	Medication-Related Osteonecrosis of the Jaw. , 2017, , .		0
184	RANK and RANK Ligand Expression in Parotid Gland Carcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 478-482.	0.6	3
185	Correlation Between Baseline Osteoprotegerin Serum Levels and Prognosis of Advanced-Stage Colorectal Cancer Patients. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 605-613.	1.1	7
186	RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis. <i>Journal of Dental Research</i> , 2018, 97, 917-927.	2.5	39
187	Mechanisms involved in normal and pathological osteoclastogenesis. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 2519-2528.	2.4	71
188	Inhibition effects of total flavonoids from <i>Scutellaria barbata</i> D. Don on human breast carcinoma bone metastasis via downregulating PTHrP pathway. <i>International Journal of Molecular Medicine</i> , 2018, 41, 3137-3146.	1.8	18
189	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. <i>Oncolmmunology</i> , 2018, 7, e1431088.	2.1	67

#	ARTICLE	IF	CITATIONS
190	Cereblon (CRBN) deletion reverses streptozotocin induced diabetic osteoporosis in mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 496, 967-974.	1.0	10
191	Downregulation of CD24 suppresses bone metastasis of lung cancer. <i>Cancer Science</i> , 2018, 109, 112-120.	1.7	23
192	Local administration of nuclear factor of activated T cells (NFAT) c1 inhibitor to suppress early resorption and inflammation induced by bone morphogenetic protein-2. <i>Journal of Biomedical Materials Research - Part A</i> , 2018, 106, 1299-1310.	2.1	8
193	A new vaccine targeting RANKL, prepared by incorporation of an unnatural Amino acid into RANKL, prevents OVX-induced bone loss in mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 499, 648-654.	1.0	10
194	1 α -Melanocyte-stimulating hormone promotes bone resorption resulting from increased osteoblastic and osteoclastic activities in goldfish. <i>General and Comparative Endocrinology</i> , 2018, 262, 99-105.	0.8	7
195	TNF- α contributes to postmenopausal osteoporosis by synergistically promoting RANKL-induced osteoclast formation. <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 369-374.	2.5	88
196	Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. <i>Molecular Psychiatry</i> , 2018, 23, 1626-1631.	4.1	48
197	Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. <i>Future Oncology</i> , 2018, 14, 195-203.	1.1	27
198	The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases. , 2018, 182, 115-132.		82
199	Naringenin inhibits osteoclastogenesis through modulation of helper T cells-secreted IL-4. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 2084-2093.	1.2	15
200	RANKL and RANK: From Mammalian Physiology to Cancer Treatment. <i>Trends in Cell Biology</i> , 2018, 28, 213-223.	3.6	72
201	Murine models of osteosarcoma: A piece of the translational puzzle. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4241-4250.	1.2	16
202	Monoclonal antibodies for treating osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 149-157.	1.4	45
203	Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 215.	0.8	14
204	Serpina3n, dominantly expressed in female osteoblasts, suppresses the phenotypes of differentiated osteoblasts in mice. <i>Endocrinology</i> , 2018, 159, 3775-3790.	1.4	15
205	Roles of the RANKL-RANK axis in antitumour immunity implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 676-693.	12.5	77
206	Bone management in hematologic stem cell transplant recipients. <i>Osteoporosis International</i> , 2018, 29, 2597-2610.	1.3	39
207	Translational models of prostate cancer bone metastasis. <i>Nature Reviews Urology</i> , 2018, 15, 403-421.	1.9	88

#	ARTICLE	IF	CITATIONS
208	Role of Toll-Like Receptor 4 on Osteoblast Metabolism and Function. <i>Frontiers in Physiology</i> , 2018, 9, 504.	1.3	55
209	Quantitation of the monoclonal antibody Denosumab by bioassay and validated LC methods. <i>International Journal of Biological Macromolecules</i> , 2018, 119, 96-104.	3.6	9
210	Low Molecular-Weight Curdlan, (1 α)- β -D-Glucan Suppresses TLR2-Induced RANKL-Dependent Bone Resorption. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 1282-1285.	0.6	13
211	Monomeric C-Reactive Protein Binds and Neutralizes Receptor Activator of NF- κ B Ligand-Induced Osteoclast Differentiation. <i>Frontiers in Immunology</i> , 2018, 9, 234.	2.2	18
212	Wnt, RSPO and Hippo Signalling in the Intestine and Intestinal Stem Cells. <i>Genes</i> , 2018, 9, 20.	1.0	49
213	Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2498-2509.	1.8	66
214	Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone. <i>Acta Biomaterialia</i> , 2018, 77, 365-379.	4.1	34
215	NF- κ B, the Importance of Being Dynamic: Role and Insights in Cancer. <i>Biomedicines</i> , 2018, 6, 45.	1.4	27
216	RANKL/RANK Pathway and Its Inhibitor RANK-Fc in Uterine Leiomyoma Growth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1842-1849.	1.8	19
217	Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumab in malignant melanoma: a retrospective analysis at a tertiary care center. <i>Melanoma Research</i> , 2018, 28, 341-347.	0.6	28
218	Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw. <i>Current Osteoporosis Reports</i> , 2018, 16, 584-595.	1.5	94
219	Genistein and Silicon Synergistically Protects Against Ovariectomy-Induced Bone Loss Through Upregulating OPG/RANKL Ratio. <i>Biological Trace Element Research</i> , 2019, 188, 441-450.	1.9	20
220	iTRAQ-based Comparative Serum Proteomic Analysis of Prostate Cancer Patients with or without Bone Metastasis. <i>Journal of Cancer</i> , 2019, 10, 4165-4177.	1.2	14
221	Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyase. <i>PLoS ONE</i> , 2019, 14, e0219734.	1.1	4
222	A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities. <i>Acta Orthopaedica Et Traumatologica Turcica</i> , 2019, 53, 376-380.	0.3	11
223	Regulation of the Bone Vascular Network is Sexually Dimorphic. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2117-2132.	3.1	19
226	The PPAR- β antagonist T007 inhibits RANKL-induced osteoclastogenesis and counteracts OVX-induced bone loss in mice. <i>Cell Communication and Signaling</i> , 2019, 17, 136.	2.7	18
227	Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2019.	2.2	130

#	ARTICLE	IF	CITATIONS
228	Chemokines in Physiological and Pathological Bone Remodeling. <i>Frontiers in Immunology</i> , 2019, 10, 2182.	2.2	99
229	Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2019, 30, 995-1002.	1.3	3
230	Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course. <i>Case Reports in Nephrology and Dialysis</i> , 2019, 9, 33-41.	0.3	11
231	Osteoblast-specific expression of Panx3 is dispensable for postnatal bone remodeling. <i>Bone</i> , 2019, 127, 155-163.	1.4	7
232	RANKL blockade suppresses pathological angiogenesis and vascular leakage in ischemic retinopathy. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 350-356.	1.0	2
233	Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1938-1951.	3.1	13
234	Molecular understanding of pharmacological treatment of osteoporosis. <i>EFORT Open Reviews</i> , 2019, 4, 158-164.	1.8	17
235	RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. <i>Acta Neuropathologica</i> , 2019, 138, 275-293.	3.9	6
236	From latency to overt bone metastasis in breast cancer: potential for treatment and prevention. <i>Journal of Pathology</i> , 2019, 249, 6-18.	2.1	45
237	Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. <i>Cancer Treatment Reviews</i> , 2019, 76, 57-67.	3.4	85
238	The RANKL-RANK Axis: A Bone to Thymus Round Trip. <i>Frontiers in Immunology</i> , 2019, 10, 629.	2.2	50
239	Murine osteoclasts secrete serine protease HtrA1 capable of degrading osteoprotegerin in the bone microenvironment. <i>Communications Biology</i> , 2019, 2, 86.	2.0	18
240	Immobilization of Denosumab on Titanium Affects Osteoclastogenesis of Human Peripheral Blood Monocytes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1002.	1.8	4
241	Low-dose cadmium exposure acts on rat mesenchymal stem cells via RANKL/OPG and downregulate osteogenic differentiation genes. <i>Environmental Pollution</i> , 2019, 249, 620-628.	3.7	22
242	Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1753-1765.	1.8	55
243	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSC-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 339-351.	5.1	167
244	The Cells of Bone and Their Interactions. <i>Handbook of Experimental Pharmacology</i> , 2019, 262, 1-25.	0.9	7
245	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFκB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). <i>Trials</i> , 2019, 20, 753.	0.7	20

#	ARTICLE	IF	CITATIONS
246	Osteoporosis in Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5867.	1.8	76
247	RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 85-91.	2.0	57
248	Pulsed electromagnetic fields regulate osteocyte apoptosis, RANKL/OPG expression, and its control of osteoclastogenesis depending on the presence of primary cilia. <i>Journal of Cellular Physiology</i> , 2019, 234, 10588-10601.	2.0	32
249	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1369-1378.	3.2	28
250	Exploring the Links Between Common Diseases of Ageing—Osteoporosis, Sarcopenia and Vascular Calcification. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2019, 17, 1-23.	1.3	15
251	ERR α promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. <i>Oncogene</i> , 2019, 38, 950-964.	2.6	25
252	Dynamics of Bone Cell Interactions and Differential Responses to PTH and Antibody-Based Therapies. <i>Bulletin of Mathematical Biology</i> , 2019, 81, 3575-3622.	0.9	12
253	RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 12.	3.5	121
254	The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. <i>Physiological Reviews</i> , 2019, 99, 115-160.	13.1	275
255	In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid. <i>Pathology and Oncology Research</i> , 2019, 25, 409-419.	0.9	29
256	SOFAT as a Putative Marker of Osteoclasts in Bone Lesions. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 448-453.	0.6	5
257	Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 351-357.	1.3	6
258	Suppression of hematopoietic cell kinase ameliorates the bone destruction associated with inflammation. <i>Modern Rheumatology</i> , 2020, 30, 85-92.	0.9	5
259	New promising avenue for the simvastatin combination with residronate, strontium ranelate and raloxifene in experimentally-induced osteoporosis. <i>Egyptian Rheumatologist</i> , 2020, 42, 63-69.	0.5	4
260	Osteoclasts. , 2020, , 111-131.		2
261	Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps. <i>Mucosal Immunology</i> , 2020, 13, 86-95.	2.7	25
262	RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 470-479.	1.1	1
263	Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?. <i>Journal of Orthopaedic Science</i> , 2020, 25, 513-519.	0.5	24

#	ARTICLE	IF	CITATIONS
264	Geneticsâ€™ Piece of the PI: Inferring the Origin of Complex Traits and Diseases from Proteomeâ€™Wide Proteinâ€™Protein Interaction Dynamics. <i>BioEssays</i> , 2020, 42, 1900169.	1.2	0
265	Pharmacological mechanisms of therapeutics. , 2020, , 1689-1710.		1
266	Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1435-1444.	1.8	26
267	Structure and Optimization of Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 38.	1.7	37
268	The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7570.	1.8	19
269	Molecular Mechanisms and Emerging Therapeutics for Osteoporosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7623.	1.8	121
270	c-Met expression in renal cell carcinoma with bone metastases. <i>Journal of Bone Oncology</i> , 2020, 25, 100315.	1.0	10
271	Systemic osteoprotegerin does not improve periâ€™implant bone volume or osseointegration in rabbits. <i>Journal of Orthopaedic Research</i> , 2020, 39, 1611-1621.	1.2	0
272	Crosstalk of Brain and Boneâ€™Clinical Observations and Their Molecular Bases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4946.	1.8	32
273	Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors. , 2020, , 403-420.		0
274	Molecular mechanisms and clinical management of cancer bone metastasis. <i>Bone Research</i> , 2020, 8, 30.	5.4	78
275	Erythropoietin receptor in B cells plays a role in bone remodeling in mice. <i>Theranostics</i> , 2020, 10, 8744-8756.	4.6	18
276	RANK and RANKL Expression in Salivary Gland Tumors. <i>Ear, Nose and Throat Journal</i> , 2020, 99, 475-480.	0.4	0
277	Secreted Osteoclastogenic Factor of Activated T Cells (SOFAT) Is Associated With Rheumatoid Arthritis and Joint Pain: Initial Evidences of a New Pathway. <i>Frontiers in Immunology</i> , 2020, 11, 1442.	2.2	5
278	Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2193.	1.7	5
279	Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls. <i>Frontiers in Oncology</i> , 2020, 10, 580605.	1.3	39
280	Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment. <i>E3S Web of Conferences</i> , 2020, 185, 03009.	0.2	1
281	Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6846.	1.8	69

#	ARTICLE	IF	CITATIONS
282	A Review of the Pharmacological Properties of Psoralen. <i>Frontiers in Pharmacology</i> , 2020, 11, 571535.	1.6	57
283	Denosumab for cancer-related bone loss. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1261-1274.	1.4	12
284	B cell acute lymphoblastic leukemia cells mediate RANK-RANKL-dependent bone destruction. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	17
285	It is time to prepare for D-CARE!. <i>Annals of Translational Medicine</i> , 2020, 8, 1339-1339.	0.7	1
286	Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1858-1870.	3.1	63
287	Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 325.	1.8	40
288	Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases. <i>Current Osteoporosis Reports</i> , 2020, 18, 401-407.	1.5	28
289	The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa008.	0.3	14
290	In silico experiments of bone remodeling explore metabolic diseases and their drug treatment. <i>Science Advances</i> , 2020, 6, eaax0938.	4.7	34
291	Calcium Homeostasis: A Potential Vicious Cycle of Bone Metastasis in Breast Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 293.	1.3	25
292	Review of Secondary Causes of Osteoporotic Fractures Due to Diabetes and Spinal Cord Injury. <i>Current Osteoporosis Reports</i> , 2020, 18, 148-156.	1.5	6
293	Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. <i>Bone Reports</i> , 2020, 13, 100293.	0.2	15
294	Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development. <i>Current Medicinal Chemistry</i> , 2020, 27, 1151-1169.	1.2	18
295	Role of the bone microenvironment in bone metastasis of malignant tumors - therapeutic implications. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 751-761.	2.1	11
296	Interaction of <i>Brucella abortus</i> with Osteoclasts: a Step toward Understanding Osteoarticular Brucellosis and Vaccine Safety. <i>Infection and Immunity</i> , 2020, 88, .	1.0	7
297	Dynamic changes of Receptor activator of nuclear factor- κ B expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. <i>Scientific Reports</i> , 2020, 10, 1288.	1.6	25
298	Pregnenolone Inhibits Osteoclast Differentiation and Protects Against Lipopolysaccharide-Induced Inflammatory Bone Destruction and Ovariectomy-Induced Bone Loss. <i>Frontiers in Pharmacology</i> , 2020, 11, 360.	1.6	15
299	Tussilagone Inhibits Osteoclastogenesis and Periprosthetic Osteolysis by Suppressing the NF- κ B and P38 MAPK Signaling Pathways. <i>Frontiers in Pharmacology</i> , 2020, 11, 385.	1.6	14

#	ARTICLE	IF	CITATIONS
300	miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss. <i>Theranostics</i> , 2020, 10, 4334-4348.	4.6	34
301	CD39 Produced from Human GMSCs Regulates the Balance of Osteoclasts and Osteoblasts through the Wnt/ β -Catenin Pathway in Osteoporosis. <i>Molecular Therapy</i> , 2020, 28, 1518-1532.	3.7	45
302	Intermittent hypoxia retards mandibular growth and alters RANKL expression in adolescent and juvenile rats. <i>European Journal of Orthodontics</i> , 2021, 43, 94-103.	1.1	1
303	Ortho-silicic Acid Inhibits RANKL-Induced Osteoclastogenesis and Reverses Ovariectomy-Induced Bone Loss In Vivo. <i>Biological Trace Element Research</i> , 2021, 199, 1864-1876.	1.9	8
304	Bad to the bone: B cell acute lymphoblastic leukemia cells mediate bone destruction. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1835423.	0.3	4
305	The endocrine role of bone: Novel functions of bone-derived cytokines. <i>Biochemical Pharmacology</i> , 2021, 183, 114308.	2.0	13
306	Osteoclast biology. , 2021, , 99-110.		0
307	Osteoporosis in organ transplant patients. , 2021, , 1281-1307.		1
308	Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways. <i>Molecular Biomedicine</i> , 2021, 2, 3.	1.7	42
309	Corydalis Saxicola Bunting Total Alkaloids Attenuate Walker 256-Induced Bone Pain and Osteoclastogenesis by Suppressing RANKL-Induced NF- κ B and c-Fos/NFATc1 Pathways in Rats. <i>Frontiers in Pharmacology</i> , 2020, 11, 609119.	1.6	7
310	Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 463-473.	1.3	10
311	Carbonic anhydrase 13 suppresses bone metastasis in breast cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100332.	0.7	4
312	Muscle-Bone Crosstalk in Chronic Kidney Disease: The Potential Modulatory Effects of Exercise. <i>Calcified Tissue International</i> , 2021, 108, 461-475.	1.5	19
313	Molecular and Cellular Basis of Bone. , 2021, , 7-10.		0
314	Denosumab for the treatment of osteoporosis. , 2021, , 1737-1755.		1
316	Severe osteoporosis: Principles for pharmacological therapy in Mexico. <i>Reumatología Clínica (English)</i> Tj ETQq1 1 0,784314,rgBT /Ove 0,2		0
317	Osthole enhances the bone mass of senile osteoporosis and stimulates the expression of osteoprotegerin by activating β -catenin signaling. <i>Stem Cell Research and Therapy</i> , 2021, 12, 154.	2.4	13
318	Association of environmental cadmium exposure and bone remodeling in women over 50 years of age. <i>Ecotoxicology and Environmental Safety</i> , 2021, 211, 111897.	2.9	10

#	ARTICLE	IF	CITATIONS
319	Giant Cell Tumor of Bone: An Update. <i>Current Oncology Reports</i> , 2021, 23, 51.	1.8	37
320	A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor. <i>Clinical and Translational Medicine</i> , 2021, 11, e368.	1.7	14
321	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 42.	2.2	11
322	Successful denosumab treatment for central giant cell granuloma in a 9-year-old child. <i>Special Care in Dentistry</i> , 2021, 41, 519-525.	0.4	11
323	Bone marrow niches in the regulation of bone metastasis. <i>British Journal of Cancer</i> , 2021, 124, 1912-1920.	2.9	35
324	Immuno-PET Molecular Imaging of RANKL in Cancer. <i>Cancers</i> , 2021, 13, 2166.	1.7	3
325	Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches. <i>Antioxidants</i> , 2021, 10, 680.	2.2	29
326	Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1245-1254.	3.1	47
327	Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 737-747.	1.3	10
328	Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 868-875.	1.3	14
329	Pharmacological Treatment of Osteoporosis in Elderly People: A Systematic Review and Meta-Analysis. <i>Gerontology</i> , 2021, 67, 639-649.	1.4	5
330	Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 824-832.	1.3	4
331	Differential effects of anti-RANKL monoclonal antibody and zoledronic acid on necrotic bone in a murine model of <i>Staphylococcus aureus</i> -induced osteomyelitis. <i>Journal of Orthopaedic Research</i> , 2022, 40, 614-623.	1.2	6
332	Interleukin-20 Acts as a Promotor of Osteoclastogenesis and Orthodontic Tooth Movement. <i>Stem Cells International</i> , 2021, 2021, 1-20.	1.2	3
333	Selective β 2-Adrenoceptor Blockade Rescues Mandibular Growth Retardation in Adolescent Rats Exposed to Chronic Intermittent Hypoxia. <i>Frontiers in Physiology</i> , 2021, 12, 676270.	1.3	4
334	Doxycycline-doped membranes induced osteogenic gene expression on osteoblastic cells. <i>Journal of Dentistry</i> , 2021, 109, 103676.	1.7	15
335	“The use of bisphosphonates to treat skeletal complications in solid tumours” <i>Bone</i> , 2021, 147, 115907.	1.4	19
336	Gram-positive bacteria cell wall-derived lipoteichoic acid induces inflammatory alveolar bone loss through prostaglandin E production in osteoblasts. <i>Scientific Reports</i> , 2021, 11, 13353.	1.6	18

#	ARTICLE	IF	CITATIONS
337	Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. Archives of Osteoporosis, 2021, 16, 116.	1.0	13
338	Fluorescence-Based Real-Time Analysis of Osteoclast Development. Frontiers in Cell and Developmental Biology, 2021, 9, 657935.	1.8	3
339	Implications of gender-based variabilities in bone mineral density and hemoglobin levels. BMC Musculoskeletal Disorders, 2021, 22, 645.	0.8	4
340	The Effects of Receptor Activator of NF- κ B Ligand-Binding Peptides on Bone Resorption and Bone Formation. Frontiers in Cell and Developmental Biology, 2021, 9, 648084.	1.8	4
341	Bone metastasis: mechanisms, therapies, and biomarkers. Physiological Reviews, 2021, 101, 797-855.	13.1	153
342	Recent Progresses in the Treatment of Osteoporosis. Frontiers in Pharmacology, 2021, 12, 717065.	1.6	28
343	Traditional application and modern pharmacological research of Eucommia ulmoides Oliv.. Chinese Medicine, 2021, 16, 73.	1.6	48
344	Blockade of adiponectin receptor 1 signaling inhibits synovial inflammation and alleviates joint damage in collagen-induced arthritis. Clinical Rheumatology, 2022, 41, 255-264.	1.0	6
345	The Roadmap of RANKL/RANK Pathway in Cancer. Cells, 2021, 10, 1978.	1.8	29
346	A systematic dissection of human primary osteoblasts in vivo at single-cell resolution. Aging, 2021, 13, 20629-20650.	1.4	19
347	Does denosumab offer survival benefits? "Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors. Journal of Thoracic Disease, 2021, 13, 4668-4677.	0.6	8
348	Targeting the RANK/RANKL pathway in autoimmune disease and malignancy: future perspectives. Expert Review of Clinical Immunology, 2021, 17, 933-936.	1.3	5
349	Osteoporosis therapies and their mechanisms of action (Review). Experimental and Therapeutic Medicine, 2021, 22, 1379.	0.8	34
350	The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects. Frontiers in Cell and Developmental Biology, 2021, 9, 735374.	1.8	16
351	A Comparison of Demographics, Disease Activity, Disability, and Treatment Among Rheumatoid Arthritis Patients with and without Osteoporosis. Open Access Rheumatology: Research and Reviews, 2021, Volume 13, 275-283.	0.8	2
352	Effect of Omeprazole on Osteoblasts and Osteoclasts in vivo and in the in vitro Model Using Fish Scales. Biochemistry (Moscow), 2021, 86, 1192-1200.	0.7	2
353	Diagnostic and Interventional Radiology Considerations in Metastatic Bone Disease. Operative Techniques in Orthopaedics, 2021, , 100893.	0.2	0
354	The histopathology of skeletal metastases. , 2022, , 771-782.		0

#	ARTICLE	IF	CITATIONS
355	Targeted Ptpn11 deletion in mice reveals the essential role of SHP2 in osteoblast differentiation and skeletal homeostasis. <i>Bone Research</i> , 2021, 9, 6.	5.4	17
356	Treatment of Chondroblastoma with Denosumab. <i>JBJS Case Connector</i> , 2021, 11, .	0.1	3
357	The Role of Autoantibodies in Bone Metabolism and Bone Loss. <i>Calcified Tissue International</i> , 2018, 102, 522-532.	1.5	11
358	Advances in the occurrence and biotherapy of osteoporosis. <i>Biochemical Society Transactions</i> , 2020, 48, 1623-1636.	1.6	42
359	HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia. <i>JCI Insight</i> , 2019, 4, .	2.3	12
360	RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. <i>Journal of Clinical Investigation</i> , 2019, 129, 3214-3223.	3.9	182
361	RANKL is a therapeutic target of bone destruction in rheumatoid arthritis. <i>F1000Research</i> , 2019, 8, 533.	0.8	25
362	Bone alterations in inflammatory bowel diseases. <i>World Journal of Clinical Cases</i> , 2019, 7, 1908-1925.	0.3	40
363	Pulsed Electromagnetic Fields Increased the Anti-Inflammatory Effect of A2A and A3 Adenosine Receptors in Human T/C-28a2 Chondrocytes and hFOB 1.19 Osteoblasts. <i>PLoS ONE</i> , 2013, 8, e65561.	1.1	106
364	Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Ameliorates Disease in Rat Collagen-Induced Arthritis. <i>PLoS ONE</i> , 2014, 9, e104530.	1.1	157
365	Physiological role of receptor activator nuclear factor- κ B (RANK) in denervation-induced muscle atrophy and dysfunction. <i>Receptors & Clinical Investigation</i> , 2016, 3, e13231-e13236.	0.9	12
366	Parathyroid Hormone Related Peptide (PTHrP): A Mini-Review. <i>Endocrinology&Metabolism International Journal</i> , 2017, 5, .	0.1	8
367	Megakaryocytes promote osteoclastogenesis in aging. <i>Aging</i> , 2020, 12, 15121-15133.	1.4	7
368	<i>BRCA1</i> haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. <i>Oncotarget</i> , 2017, 8, 35019-35032.	0.8	12
369	Increased breast tissue receptor activator of nuclear factor- κ B ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. <i>Oncotarget</i> , 2017, 8, 73787-73792.	0.8	12
370	Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. <i>Oncotarget</i> , 2014, 5, 6647-6653.	0.8	27
371	Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. <i>Oncotarget</i> , 2017, 8, 94834-94849.	0.8	117
372	Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin. <i>Oncotarget</i> , 2016, 7, 23498-23511.	0.8	25

#	ARTICLE	IF	CITATIONS
393	å½“é™«ãšãš,ãf†ãfžã,ãfžãf-ã½ç”æ^ç,¾èªæŸ». Orthopedics & Traumatology, 2016, 65, 581-584.	0.0	0
394	Ca2+- und Knochenstoffwechsel. Springer-Lehrbuch, 2016, , 627-637.	0.1	0
395	Bone-Targeted Agents. , 2017, , 181-192.		0
396	Molecular Pathogenesis of Bone Tumours. , 2017, , 41-63.		0
397	Title is missing!. Orthopedics & Traumatology, 2017, 66, 346-349.	0.0	0
398	Expression of microRNA related to bone remodeling regulation in plasma in patients with acromegaly. Obesity and Metabolism, 2017, 14, 32-37.	0.4	2
399	Botresorptieremmers en preventie van osteonecrose van de kaak. , 2018, , 169-182.		0
400	Novel mediators of breast cancer bone metastasis—insights from studies of gene-regulation and the global proteome. Annals of Translational Medicine, 2018, 6, S71-S71.	0.7	0
401	Systemic Therapies for Patients with Metastatic Spinal Disease. , 2020, , 513-522.		0
403	Cellular Contributors to Bone Homeostasis. Contemporary Cardiology, 2020, , 333-371.	0.0	2
404	Translational Pharmacology in The Development of RANKL Inhibitors. , 2020, , 590-598.		0
405	Ca2+- und Knochenstoffwechsel. , 2020, , 661-671.		1
406	Transplantation Osteoporosis. Contemporary Endocrinology, 2020, , 419-448.	0.3	3
407	Denosumab inhibits MCF-7 cell line-induced spontaneous osteoclastogenesis via the RANKL/MALAT1/miR-124 axis. Translational Cancer Research, 2020, 9, 2482-2491.	0.4	4
408	Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. American Journal of Clinical and Experimental Urology, 2014, 2, 92-101.	0.4	18
409	Regulation of osteogenic differentiation by DNA methylation of the dishevelled gene in bone marrow mesenchymal stem cells. American Journal of Translational Research (discontinued), 2017, 9, 4848-4855.	0.0	3
410	Multiplexed Molecular Imaging Strategy Integrated with RNA Sequencing in the Assessment of the Therapeutic Effect of Whartonâ€™s Jelly Mesenchymal Stem Cell-Derived Extracellular Vesicles for Osteoporosis. International Journal of Nanomedicine, 2021, Volume 16, 7813-7830.	3.3	7
411	Denosumab in the Treatment of Postmenopausal Women with Osteoporosis: Fracture Outcomes, BMD, and Morphological Assessment. , 2022, , 377-388.		0

#	ARTICLE	IF	CITATIONS
412	Hypercalcemia following discontinuation of denosumab therapy: A systematic review. Bone Reports, 2021, 15, 101148.	0.2	17
413	Histomorphometry of Remodeling and Modeling-Based Mineral Apposition. , 2022, , 47-65.		0
414	Antibody Treatment and Osteoporosis: Clinical Perspective. Springer Series in Biomaterials Science and Engineering, 2022, , 111-126.	0.7	0
416	Expression of Receptor Activator of Nuclear κ Ligand in Patients with Metastatic Bone Disease. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 57-62.	0.1	0
417	PTH1R Actions on Bone Using the cAMP/Protein Kinase A Pathway. Frontiers in Endocrinology, 2021, 12, 833221.	1.5	8
418	Comparative study of holothurin A and echinoside A on inhibiting the high bone turnover <i>via</i> downregulating PI3K/AKT/ β -catenin and OPG/RANKL/NF- κ B signaling in ovariectomized mice. Food and Function, 2022, 13, 4748-4756.	2.1	7
419	American Association of Oral and Maxillofacial Surgeons™ Position Paper on Medication-Related Osteonecrosis of the Jaws™2022 Update. Journal of Oral and Maxillofacial Surgery, 2022, 80, 920-943.	0.5	312
420	Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years. Journal of Bone and Mineral Research, 2020, 37, 856-864.	3.1	8
421	Roles of the RANKL-RANK Axis in Immunity” Implications for Pathogenesis and Treatment of Bone Metastasis. Frontiers in Immunology, 2022, 13, 824117.	2.2	21
422	Bispecific Antibodies Progression in Malignant Melanoma. Frontiers in Pharmacology, 2022, 13, 837889.	1.6	0
423	Machine Learning Algorithms: Prediction and Feature Selection for Clinical Refracture after Surgically Treated Fragility Fracture. Journal of Clinical Medicine, 2022, 11, 2021.	1.0	3
424	Osteoclastic and Osteoblastic Responses to Hypergravity and Microgravity: Analysis Using Goldfish Scales as a Bone Model. Zoological Science, 2022, 39, .	0.3	5
425	RANKL biology. Bone, 2022, 159, 116353.	1.4	38
426	Bortezomib Rescues Ovariectomy-Induced Bone Loss via SMURF-Mediated Ubiquitination Pathway. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-17.	1.9	11
427	Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta. Cells, 2022, 11, 1357.	1.8	3
428	Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with ⁹⁰ Y or ¹⁷⁷ Lu. Journal of Medicinal Chemistry, 2022, 65, 6419-6430.	2.9	2
429	Anti-RANKL Inhibits Thymic Function and Causes DRONJ in Mice. International Journal of Dentistry, 2022, 2022, 1-9.	0.5	0
432	Bone Metastases: From Mechanisms to Treatment. Seminars in Oncology Nursing, 2022, , 151277.	0.7	5

#	ARTICLE	IF	CITATIONS
433	Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies. <i>BioMed Research International</i> , 2022, 2022, 1-23.	0.9	5
434	Denosumab and Risk of Community-acquired Pneumonia: A Population-based Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3366-e3373.	1.8	3
435	The Roles of RANK/RANKL/OPG in Cardiac, Skeletal, and Smooth Muscles in Health and Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	23
436	Progress in research of non-cirrhotic chronic viral hepatitis with osteoporosis. <i>World Chinese Journal of Digestology</i> , 2022, 30, 491-497.	0.0	0
437	Ganoderic acid A improves osteoarthritis by regulating <sc>RANKL</sc>/<sc>OPG</sc> ratio. <i>Chemical Biology and Drug Design</i> , 2022, 100, 313-319.	1.5	1
438	Exploring new pathways in endocrine-resistant breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 337-361.	0.5	2
439	Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study. <i>Osteoporosis International</i> , 0, , .	1.3	7
440	The 100 most cited papers on bone metastasis: A bibliometric analysis. <i>Journal of Bone Oncology</i> , 2022, 35, 100443.	1.0	3
441	Guanylyl Cyclase-B Dependent Bone Formation in Mice is Associated with Youth, Increased Osteoblasts, and Decreased Osteoclasts. <i>Calcified Tissue International</i> , 2022, 111, 506-518.	1.5	2
442	Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database. <i>Drugs - Real World Outcomes</i> , 2022, 9, 659-665.	0.7	4
443	Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor- κ B Ligand. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 10992-11009.	2.9	5
444	Drug targets and drug-target molecules. , 2022, , 97-149.		0
445	Systemic Regulation of Metastatic Disease by Extracellular Vesicles and Particles. , 2022, , 9-39.		0
446	Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis. <i>Nature Communications</i> , 2022, 13, .	5.8	11
447	Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1133-1142.	1.9	1
448	Yaşlı yetişkinlerde osteoporoz tedavisinde antirezorptif ajanların kararlaştırılması. <i>Cukurova Medical Journal</i> , 2022, 47, 1248-1255.	0.1	0
449	Molecular mechanisms, physiological roles, and therapeutic implications of ion fluxes in bone cells: Emphasis on the cation- Ca^{2+} cotransporters. <i>Journal of Cellular Physiology</i> , 0, , .	2.0	2
450	A bibliometric research based on hotspots and frontier trends of denosumab. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1

#	ARTICLE	IF	CITATIONS
451	Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation. <i>Current Osteoporosis Reports</i> , 2022, 20, 505-515.	1.5	11
452	RANK pathway in cancer: underlying resistance and therapeutic approaches. <i>Journal of Chemotherapy</i> , 2023, 35, 369-382.	0.7	1
453	Skeletal consequences of heart failure. <i>Women's Health</i> , 2022, 18, 174550572211355.	0.7	2
454	Phosphatidylserine liposome multilayers mediate the M1-to-M2 macrophage polarization to enhance bone tissue regeneration. <i>Acta Biomaterialia</i> , 2022, 154, 583-596.	4.1	24
455	Sexing Bones: Improving Transparency of Sex Reporting to Address Bias Within Preclinical Studies. <i>Journal of Bone and Mineral Research</i> , 2020, 38, 5-13.	3.1	5
456	Tumor Microenvironment, Clinical Features, and Advances in Therapy for Bone Metastasis in Gastric Cancer. <i>Cancers</i> , 2022, 14, 4888.	1.7	7
457	Emerging trends and focus of giant cell tumor of bone research from 2001â€“2021: A visualization research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
458	The Innate Immune Microenvironment in Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5986.	1.0	3
459	Where is bone science taking us?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, , 101791.	1.4	1
460	Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer. , 2022, 1, .		13
461	Discontinuation of denosumab in men with prostate cancer. <i>Osteoporosis International</i> , 2023, 34, 291-297.	1.3	3
462	Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. <i>BMC Musculoskeletal Disorders</i> , 2022, 23, .	0.8	2
463	Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5727.	1.7	9
464	Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease. <i>Nature Communications</i> , 2022, 13, .	5.8	4
465	Denosumab Discontinuation. <i>Current Osteoporosis Reports</i> , 2023, 21, 95-103.	1.5	7
466	Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption. <i>Osteoporosis International</i> , 2023, 34, 599-605.	1.3	4
467	Abaloparatide Improves Rotator Cuff Healing Via Anabolic Effects on Bone Remodeling in a Chronic Rotator Cuff Tear Model of Rat With Osteoporosis: A Comparison With Denosumab: Response. <i>American Journal of Sports Medicine</i> , 2023, 51, NP3-NP4.	1.9	0
468	RANKL and RANK in Cancer Therapy. <i>Physiology</i> , 2023, 38, 110-124.	1.6	1

#	ARTICLE	IF	CITATIONS
469	Clostridium butyricum Can Promote Bone Development by Regulating Lymphocyte Function in Layer Pullets. International Journal of Molecular Sciences, 2023, 24, 1457.	1.8	1
470	Bone Metastasis in Bladder Cancer. Journal of Personalized Medicine, 2023, 13, 54.	1.1	2
471	Periplocin targets low density lipoprotein receptor-related protein 4 to attenuate osteoclastogenesis and protect against osteoporosis. Biochemical Pharmacology, 2023, 211, 115516.	2.0	1
472	Targeting ROS-induced osteoblast senescence and RANKL production by Prussian blue nanozyme based gene editing platform to reverse osteoporosis. Nano Today, 2023, 50, 101839.	6.2	5
473	Denosumab Use in Rats: Response. American Journal of Sports Medicine, 2023, 51, NP8-NP10.	1.9	0
474	Astragalus Polysaccharides Alleviate Lung Adenocarcinoma Bone Metastases by Inhibiting the CaSR/PTHrP Signaling Pathway. Journal of Food Biochemistry, 2023, 2023, 1-20.	1.2	0
475	Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Frontiers in Oncology, 0, 13, .	1.3	4
477	Dual Role of Interleukin-20 in Different Stages of Osteoclast Differentiation and Its Osteoimmune Regulation during Alveolar Bone Remodeling. International Journal of Molecular Sciences, 2023, 24, 3810.	1.8	2
478	Causal effects for genetic variants of osteoprotegerin on the risk of acute myocardial infarction and coronary heart disease: A two-sample Mendelian randomization study. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
479	Effects of anti-RANKL antibodies administered to pregnant mice on bone and tooth development in neonates. Journal of Oral Biosciences, 2023, , .	0.8	0
480	The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy. Breast Cancer Research, 2023, 25, .	2.2	0
481	MRONJ Treatment Strategies: A Systematic Review and Two Case Reports. Applied Sciences (Switzerland), 2023, 13, 4370.	1.3	5
482	CCL12 induces trabecular bone loss by stimulating RANKL production in BMSCs during acute lung injury. Experimental and Molecular Medicine, 2023, 55, 818-830.	3.2	1
483	The Role of Denosumab in the Treatment of Primary Tumors of Bone. Journal of Hand Surgery, 2023, 48, 923-930.	0.7	0
484	Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study. BMJ, The, 0, , e073435.	3.0	8
505	Denosumab: Clinical Applications, Outcomes, and Perspectives in Osteoporosis. , 2023, , 21-34.		0
507	Structure and function of the membrane microdomains in osteoclasts. Bone Research, 2023, 11, .	5.4	0
517	Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases. Experimental and Molecular Medicine, 2024, 56, 264-272.	3.2	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------